Biocept
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
9955 Mesa Rim Rd, San Diego, California,...Phone Number
(858) 320-8200Website
www.biocept.comRevenue
<$5 MillionStock Symbol
BIOCIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Biocept
Biocept, Inc. develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its broad portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes cerebrospinal fluid tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. Biocept also is leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.Explore more
Biocept Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Biocept your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Biocept has new funding data
Click to see if Biocept had a recent Job posting/layoffs
Earning: See what the market has to say on Biocept recently announced quarterly report
Check out if Biocept is spiking on competitors!
Check if Biocept has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Biocept launches new products
Congratulate Masked Content for being promoted to Masked Content at Biocept
Biocept, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Biocept
Find 3 more new buyers
Compare Similar Companies to Biocept
Compare insights from companies similar to Biocept, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Biocept is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Biocept is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Biocept.
Biocept financials insights
Gather financial insights about Biocept, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2010
Series C
$3.6M
Series D
$2.3M
2011
Debt
$1.2M
2014
Stock Offering
$19M
2017
Share Placement
$9.3M
2018
Stock Offering
$13.3M
2019
Stock Offering
$10M
2020
Multiple Rounds
$26.1M
Biocept Tech Stack
A closer look at the technologies used by Biocept
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Executive Move
Board of Directors
Executive Move
Board of Directors
Executive Move
Board of Directors
Promotion
Executive Move
Biocept News & Media
Why Is Cancer Diagnostic Focused Biocept Stock Trading Higher Today?
Biocept Inc (NASDAQ: BIOC) shares are trading higher after the company signed a non-exclusive licensing agreement for CNSide with Plus Therapeutics Inc (NASDAQ: PSTV), which expands the comprehensive laboratory services agreement between the two companies that was announced in June 2022. Benzinga exclusively broke the story. Plus Therapeutics is using CNSide in a clinical trial with their targeted radiotherapeutic to treat patients with carcinomas and/or melanomas with suspected leptomeningeal mBiocept Signs CNSide™ Licensing Agreement with Plus Therapeutics
SAN DIEGO--(BUSINESS WIRE)---- $BIOC #CSF--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, announces the signing of a non-exclusive licensing agreement for CNSide™ with Plus Therapeutics, Inc. (Nasdaq: PSTV) (Plus), which expands the comprehensive laboratory services agreement between the two companies that was announced in June 2022. Plus is using CNSide in a clinical trial with their targeted radiotherapeutic to treat patients with carciBiocept to Participate in the H.C. Wainwright Global Investment Conference
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and services, announces that management will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023. A webcast of the Biocept presentation will be available on the Events & Presentation section of the Company’s website beginning Monday, September 11 at 7:00 a.m. Eastern time. Management is avaBiocept, Inc. (BIOC) Business Update Conference Call (Transcript)
Biocept, Inc. (NASDAQ:NASDAQ:BIOC) Business Update Conference Call August 30, 2023 4:00 PM ETCompany ParticipantsJody Cain - LHAAntonino Morales - President, CEODr.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Biocept
Sign Up For FreeTo access detailed company insights
Biocept, Inc. develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its broad portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects... Read More
